Our cell therapy product candidate pipeline is comprised of first-in-class cellular immunotherapies for cancer and autoimmune diseases. Our programs reflect our dedication and commitment to pioneering ground breaking science to address severe, life-threatening diseases where the unmet need is significant and the treatment options are limited.
| Program (Cell Type) | Indication | CAR Target(s) | Research | Preclinical | Phase 1 | Partner |
|---|---|---|---|---|---|---|
| CAR T-cell Product Candidates | ||||||
| FT819 | Systemic Lupus Erythematosus | CD19 |
|
 |
||
| FT819 | AAV, IIM, SSc | CD19 |
|
|||
| FT825 | Solid Tumors | HER2/EGFR |
|
|||
| Undisclosed | Solid Tumors | Undisclosed |
|
 |
||
| FT836 | Broad Spectrum in Solid Tumor w/o CC | MICA/B |
|
|||
| FT839 | Broad Spectrum in Autoimmune w/o CC | CD19/CD38 |
|
|||
| FT8XX | Multiple Therapeutic Areas | Undisclosed |
|
|||
| CAR NK Cell Product Candidates | ||||||
| FT522 | Autoimmunity w/o CC | CD19, 4-1BB |
|
|||
| NG iNKs | Multiple Therapeutic Areas | Undisclosed |
|
|||
CAR T-cell Product Candidates
| Program | Indication | CAR Target(s) | Phase |
|---|---|---|---|
| FT819 | Systemic Lupus Erythematosus | CD19 | Ph 1 |
| FT819 | AAV, IIM, SSc | CD19 | Ph 1 |
| FT825 | Solid tumors | HER2/EGFR | Ph 1 |
| Undisclosed | Solid Tumors | Undisclosed | PreClin |
| FT836 | Broad Spectrum in Solid Tumor w/o CC | MICA/B | PreClin |
| FT839 | Broad Spectrum in Autoimmune w/o CC | CD19/CD38 | PreClin |
| FT8XX | Multiple Therapeutic Areas | Undisclosed | PreClin |
CAR NK cell Product Candidates
| Program | Indication | CAR Target(s) | Phase |
|---|---|---|---|
| FT522 | Autoimmunity w/o CC | CD19, 4-1BB | Ph 1 |
| NG iNKs | Multiple Therapeutic Areas | Undisclosed | PreClin |
AAV = Antineutrophilic cytoplasmic anti-body associated vasculitis CC = Conditioning chemotherapy IIM = Idiopathic Inflammatory Myositis NG = Next-generation SSc = Systemic Sclerosis US rights to all products